Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 8INDUSTRY 3OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Myeloid 1Head & Neck 1Endocrine 1CNS 1

Conditions

Oligodendroglioma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Neoplasms 1Histiocytosis, Langerhans-Cell 1Glioma 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1Differentiated Thyroid Cancer (DTC) 1Astrocytoma 1

Interventions

pembrolizumab 131Carboplatin 106Paclitaxel 66Cisplatin 61Gemcitabine 57Pemetrexed 56Bevacizumab 50Docetaxel 47Fluorouracil 40Oxaliplatin 38Dexamethasone 34130-nm albumin-bound paclitaxel 34Leucovorin 33atezolizumab 32Cetuximab 32durvalumab 30Nivolumab 28Rituximab 26Cyclophosphamide 26Capecitabine 26Prednisone 25Fulvestrant 24enzalutamide 23Lenalidomide 22venetoclax 21Letrozole 20Irinotecan 20Doxorubicin 17ribociclib 16pomalidomide 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × trametinib × 30 days × Clear all
NCT04940052 2026-06-04

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Novartis

Phase 3 Active not recruiting
153 enrolled 15 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

NCT03899155 2026-06-03

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting
1,500 enrolled
Tumor-Agnostic

Neoplasms

NCT03975829 2026-06-02

Pediatric Long-Term Follow-up and Rollover Study

Novartis

Phase 4 Recruiting
165 enrolled
CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡